BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Aciphex (Rabeprazole) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Aciphex (Rabeprazole)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07888569-3870@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20261123
DTEND;VALUE=DATE:20261124
SUMMARY:Aciphex (Rabeprazole): Phase 1 readout est. (NCT07888569)
DESCRIPTION:Aciphex (Rabeprazole)\, phase 1.\nStudy: Assessing the Effect o
 f a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Pa
 rticipants (TAI-SHAN21)\nEstimated primary completion: 23 November 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/rabeprazole#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07888569
URL:https://assetmemo.bio/drug/rabeprazole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06349486-3870@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Aciphex (Rabeprazole): Phase na readout est. (NCT06349486)
DESCRIPTION:Aciphex (Rabeprazole)\, phase na.\nStudy: Efficacies of Bismuth
 -amoxicillin-vonoprazan Triple Therapy\, Vonoprazan-amoxicillin Dual Thera
 py and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradicat
 ion\nEstimated primary completion: 31 December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/rabeprazole#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06349486
URL:https://assetmemo.bio/drug/rabeprazole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797478-3870@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270615
DTEND;VALUE=DATE:20270616
SUMMARY:Aciphex (Rabeprazole): Phase 1 readout est. (NCT07797478)
DESCRIPTION:Aciphex (Rabeprazole)\, phase 1.\nStudy: A Study of RO7890597 i
 n Healthy Adult Volunteers\nEstimated primary completion: 15 June 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/rabeprazole#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07797478
URL:https://assetmemo.bio/drug/rabeprazole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07358130-3870@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20271115
DTEND;VALUE=DATE:20271116
SUMMARY:Aciphex (Rabeprazole): Phase na readout est. (NCT07358130)
DESCRIPTION:Aciphex (Rabeprazole)\, phase na\, Helicobacter pylori Infectio
 n.\nStudy: Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and
  Bismuth Quadruple Therapy\nEstimated primary completion: 15 November 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/rabeprazole#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07358130
URL:https://assetmemo.bio/drug/rabeprazole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06630234-3870@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Aciphex (Rabeprazole): Phase 1/2 readout est. (NCT06630234)
DESCRIPTION:Aciphex (Rabeprazole)\, phase 1/2.\nStudy: A Master Protocol to
  Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)\nEstimated pri
 mary completion: May 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/rabeprazole#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06630234
URL:https://assetmemo.bio/drug/rabeprazole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07471867-3870@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20280712
DTEND;VALUE=DATE:20280713
SUMMARY:Aciphex (Rabeprazole): Phase 4 readout est. (NCT07471867)
DESCRIPTION:Aciphex (Rabeprazole)\, phase 4.\nStudy: Effect of ZaStaprazan 
 on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRven
 tion\nEstimated primary completion: 12 July 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/rabeprazole#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07471867
URL:https://assetmemo.bio/drug/rabeprazole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07788053-3870@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Aciphex (Rabeprazole): Phase na readout est. (NCT07788053)
DESCRIPTION:Aciphex (Rabeprazole)\, phase na\, Helicobacter pylori Infectio
 n.\nStudy: Efficacy And Safety of Bismuth-Tetracycline-Rabeprazole Triple 
 For First-Line Eradication of Helicobacter Pylori Infection\nEstimated pri
 mary completion: 1 September 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/rabeprazole#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07788053
URL:https://assetmemo.bio/drug/rabeprazole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
